Five key drug discovery deals of summer 2023
Drug Discovery World
AUGUST 9, 2023
The new acquisition gives Biogen rights to Reata’s portfolio of products for neurological diseases, including the FDA-approved Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s ataxia (FA) in the United States.
Let's personalize your content